| Patient | Gilda Radner |
|---|---|
| Date of birth | 1986-06-28 |
| Identifiers | MRN HR-ML026-SYN; SSN (made up) 000-26-8821 |
| Document date | 2026-05-12 |
| Author | Delia Marchand, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review three weeks after cytoreductive surgery, on the first chemotherapy day. [S]
Ms. Radner returns three weeks after primary cytoreductive surgery: hysterectomy with removal of both tubes and ovaries, total omentectomy, stripping of the right diaphragm, and excision of pelvic nodules, with no visible disease left. She went home on the fifth day. The wound has healed. She is giving herself enoxaparin each evening and will finish the 28 days next week; she has had no bleeding or leg swelling. She needed acetaminophen for two weeks and nothing now. Her appetite is back and the bloating has gone. Since surgery she has hot flashes several times a day and night sweats. She came this morning for her first cycle of carboplatin and paclitaxel. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Operation | Complete gross resection; home on day 5; wound healed |
| Pathology | High-grade serous carcinoma of both ovaries, pT3c, FIGO stage IIIC; serous tubal intraepithelial carcinoma in the right tube |
| Genetic results | Germline panel negative; tumor BRCA1 pathogenic variant; homologous recombination deficient |
| Symptoms | Bloating gone; appetite normal; new hot flashes and night sweats |
| Medicines | Enoxaparin, one week left; no pain medicine |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Night sweats with hot flashes; no fever; weight 55.2 kg |
| Gastrointestinal | Negative | No bloating, nausea or vomiting; bowels normal |
| Genitourinary | Negative | No urinary symptoms or vaginal bleeding |
| Neurological | Negative | No tingling or numbness in the hands or feet |
| Cardiovascular | Negative | No calf pain or leg swelling |
| Endocrine | Positive | Hot flashes several times a day since surgery |
| Psychiatric | Negative | Mood fair; PHQ-9 5; no thoughts of self-harm |
7 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Enoxaparin 40 mg/0.4 mL prefilled syringe, 40 mg under the skin once daily for 28 days after surgery | 40 mg under the skin once daily for 28 days | Subcutaneous route | 2026-04-21 to 2026-05-18 | completed | S |
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a day | Two tablets every 6 hours as needed | Oral route | 2026-04-21 to 2026-05-05 | completed | S |
| Carboplatin 10 mg/mL injection, 610 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cycles | Day 1 every 21 days for six cycles | Intravenous route | 2026-05-12 to 2026-08-25 | completed | S |
| Paclitaxel 6 mg/mL injection, 275 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidine | Day 1 every 21 days for six cycles | Intravenous route | 2026-05-12 to 2026-08-25 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea | One tablet every 8 hours as needed for nausea | Oral route | 2026-05-12 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-12 | Body height | 160 | cm | S |
| 2026-05-12 | Body weight | 55.2 | kg | S |
| 2026-05-12 | Body mass index (BMI) [Ratio] | 21.6 | kg/m2 | S |
| 2026-05-12 | Systolic blood pressure | 112 | mm[Hg] | S |
| 2026-05-12 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 2026-05-12 | Heart rate | 84 | /min | S |
| 2026-05-12 | Respiratory rate | 14 | /min | S |
| 2026-05-12 | Body temperature | 36.7 | Cel | S |
| 2026-05-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-12 | Hemoglobin [Mass/volume] in Blood | 10.9 | g/dL | 11.6-15 g/dL | Low | S |
| 2026-05-12 | Leukocytes [#/volume] in Blood by Automated count | 6.9 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2026-05-12 | Neutrophils [#/volume] in Blood by Automated count | 4.2 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2026-05-12 | Platelets [#/volume] in Blood by Automated count | 356 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-05-12 | Creatinine [Mass/volume] in Serum or Plasma | 0.68 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-05-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 114 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-12 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 7-35 U/L | Normal | S |
| 2026-05-12 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 20 | U/L | 8-35 U/L | Normal | S |
| 2026-05-12 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.4 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-05-12 | Albumin [Mass/volume] in Serum or Plasma | 3.7 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-05-12 | Magnesium [Mass/volume] in Serum or Plasma | 1.9 | mg/dL | 1.7-2.2 mg/dL | Normal | S |
| 2026-05-12 | Cancer Ag 125 [Units/volume] in Serum or Plasma | 188 | U/mL | <=35 U/mL | High | S |
| 2026-05-12 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 2026-05-12 | Pain severity - 0-10 verbal numeric rating [Score] - Reported | 2 | {score} | S |
Vital signs recorded on 2026-05-12; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 112/70, pulse 84; weight 55.2 kg |
| Abdomen | Midline incision healed without redness or hernia; soft, non-tender; no fluid |
| Neurological | Light touch, pinprick and vibration normal in the hands and feet; ankle reflexes present (baseline before paclitaxel) |
| Extremities | No calf tenderness or swelling; injection sites on the abdomen clean |
| Psychiatric | Engaged and joking; organized |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Persistent bloating with tightness of her clothes, feeling full after a few bites, a dull lower abdominal and pelvic ache, and passing urine more often, on most days for about four weeks, in a woman of 39: the ovarian cancer symptom index is positive. Examination: a distended abdomen with shifting dullness and a firm, fixed, irregular mass in the right adnexa. Suspected ovarian cancer; transvaginal ultrasound, CT, CA-125 and gynecologic oncology review booked within the week | resolved | confirmed | R19.00 | S — Synthetic presenting problem linked to her documented abdominal symptoms; superseded by the diagnosis at the gynecologic oncology consultation. |
| High-grade serous carcinoma of both ovaries (Mullerian origin), diagnosed by image-guided omental core biopsy (PAX8 and WT1 positive, p53 aberrant), with bilateral adnexal masses, ascites, omental and diaphragmatic disease on CT: clinical FIGO stage IIIC; synthetic modern detail linked to her documented ovarian cancer | active | confirmed | C56.3 | S — Synthetic histology and stage; the documented diagnosis was stage IV ovarian cancer (D). |
| Peritoneal and omental metastases of the ovarian cancer, with ascites | active | confirmed | C78.6 | S — Synthetic extent of disease on CT and biopsy. |
| Family history of ovarian cancer in three relatives (her grandmother, an aunt, and a cousin) in a woman of Ashkenazi Jewish ancestry; no genetic testing in the family is known | active | confirmed | Z80.41 | S — Synthetic coding of her documented family history; the basis for genetic counseling. |
| Symptomatic surgical menopause after bilateral salpingo-oophorectomy at 39: hot flashes and night sweats | active | confirmed | E89.41 | S — Synthetic consequence of the synthetic operation. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Surgical pathology and stage | After surgery | Up to date | High-grade serous carcinoma, pT3c, FIGO stage IIIC; no visible residual disease |
| Laboratory | Germline multigene panel | Once, at diagnosis | Completed today | Reviewed with her: no pathogenic variant in BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 or the Lynch syndrome genes |
| Laboratory | Tumor testing for BRCA1 and BRCA2 and homologous recombination deficiency | On the surgical specimen, before the maintenance decision | Completed today | Tumor BRCA1 pathogenic variant (somatic, as the germline test is negative); homologous recombination deficient |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before chemotherapy | Up to date | All negative; no antiviral prophylaxis needed |
| Laboratory | Blood count with neutrophils and platelets | Before each chemotherapy cycle | Completed today | Hemoglobin 10.9 g/dL after surgery, white cells 6.9, neutrophils 4.2, platelets 356 |
| Laboratory | Creatinine and estimated kidney function (carboplatin dose) | Before each cycle | Completed today | Creatinine 0.68 mg/dL, eGFR 114; carboplatin 610 mg for AUC 5 |
| Laboratory | Liver tests (paclitaxel) | Before each cycle | Completed today | ALT 21, AST 20 U/L, bilirubin 0.4 mg/dL, albumin 3.7 g/dL |
| Laboratory | Magnesium | Before each cycle | Completed today | 1.9 mg/dL |
| Laboratory | CA-125 | At diagnosis; before each cycle when raised at diagnosis; at the end of treatment; then at each surveillance visit | Completed today | 188 U/mL, from 1240 before surgery |
| Examination | Peripheral neuropathy: symptoms and examination | At baseline and before each taxane cycle | Completed today | Baseline normal before the first paclitaxel dose |
| Medication safety | Nausea and vomiting control | Each cycle | Completed today | Three-drug preventive regimen for carboplatin (an NK1 antagonist, a 5-HT3 antagonist and dexamethasone); ondansetron at home |
| Medication safety | Paclitaxel infusion reaction prevention | Each paclitaxel dose | Completed today | Dexamethasone, diphenhydramine and famotidine before the infusion; first-hour observation |
| Medication safety | Thromboprophylaxis after cancer surgery | From surgery for four weeks | Completed today | Day 22 of 28 of enoxaparin; no bleeding or leg swelling |
| Examination | Wound review | After surgery | Completed today | Healed, without hernia |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, at each treatment phase, and when symptoms change | Completed today | PHQ-9 5; no thoughts of self-harm |
| Survey | Pain score | Each visit after surgery | Completed today | Worst pain 2 of 10; no pain medicine |
| Self-management | Menopausal symptoms after oophorectomy | Each visit after surgery | Completed today | Hot flashes several times a day and night sweats; non-hormonal measures |
| Self-management | Psychosocial support and information | At diagnosis and throughout | Completed today | Joined a cancer support community group last week |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 4.2026 (2026); Konstantinopoulos PA, et al. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. J Clin Oncol 2020;38(11):1222-1245 (2020); Tew WP, et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol 2020;38(30):3468-3493 (2020); Salani R, et al. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017;146(1):3-10 (2017); Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (2023); Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020;38(24):2782-2797 (2020); Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (2020); Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020 (2020); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Cycles every 21 days in the infusion center. Primary care and gynecologic oncology review at cycle 4. Call at once for a temperature of 38.0 °C or more. Next scheduled visit 2026-07-14: midpoint of chemotherapy: CA-125, blood counts, neuropathy, and menopausal symptoms. [S]